0001104659-23-010108.txt : 20230203
0001104659-23-010108.hdr.sgml : 20230203
20230203060207
ACCESSION NUMBER: 0001104659-23-010108
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230202
FILED AS OF DATE: 20230203
DATE AS OF CHANGE: 20230203
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: SHALLCROSS STEVEN A
CENTRAL INDEX KEY: 0001263501
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-12584
FILM NUMBER: 23583606
BUSINESS ADDRESS:
STREET 1: C/O ELYS GAME TECHNOLOGY CORP.
STREET 2: 130 ADELAIDE STREET WEST, SUITE 701
CITY: TORONTO
STATE: A6
ZIP: M5H2K4
BUSINESS PHONE: 301 944 6600
MAIL ADDRESS:
STREET 1: C/O ELYS GAME TECHNOLOGY CORP.
STREET 2: 130 ADELAIDE STREET WEST, SUITE 701
CITY: TORONTO
STATE: A6
ZIP: M5H2K4
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Theriva Biologics, Inc.
CENTRAL INDEX KEY: 0000894158
STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834]
IRS NUMBER: 133808303
STATE OF INCORPORATION: NV
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9605 MEDICAL CENTER DRIVE
STREET 2: SUITE 270
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: (734) 332-7800
MAIL ADDRESS:
STREET 1: 9605 MEDICAL CENTER DRIVE
STREET 2: SUITE 270
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: Synthetic Biologics, Inc.
DATE OF NAME CHANGE: 20120305
FORMER COMPANY:
FORMER CONFORMED NAME: ADEONA PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20081027
FORMER COMPANY:
FORMER CONFORMED NAME: PIPEX PHARMACEUTICALS, INC.
DATE OF NAME CHANGE: 20061214
4
1
tm235343-1_4seq1.xml
OWNERSHIP DOCUMENT
X0306
4
2023-02-02
0
0000894158
Theriva Biologics, Inc.
TOVX
0001263501
SHALLCROSS STEVEN A
C/O THERIVA BIOLOGICS, INC.,
9605, MEDICAL CENTER DRIVE, SUITE 270
ROCKVILLE
MD
20850
1
1
0
0
CEO and CFO
Common Stock
2023-02-02
4
P
0
25000
0.9405
A
185000
D
The price reported in Column 4 is a weighted average price. These shares were acquired in multiple transactions at prices ranging from $0.9349 through $0.9499, inclusive. The reporting person undertakes to provide to the registrant, any security holder of the registrant, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
/s/ Steven A. Shallcross
2023-02-02